Accuray Inc. Release: First CyberKnife System to be Installed in Canada
SUNNYVALE, Calif., June 26 /PRNewswire-FirstCall/ -- Accuray Incorporated , a global leader in the field of radiosurgery today announced that Centre Hospitalier de l'Universite de Montreal (CHUM) has purchased a CyberKnife(R) Robotic Radiosurgery System for installation at Hopital Notre-Dame du CHUM, in Montreal, Canada.
CHUM, one of the largest radiation oncology centers in Canada, will utilize the CyberKnife System to treat both intracranial and extracranial tumors including those in the lung, spine and prostate.
CHUM is one of the leading academic sites in North America for the number of accruals for protocols developed by the Radiation Therapy Oncology Group (RTOG) of the American College of Radiology (ACR), demonstrating the center's leadership in research and innovation.
"In addition to being an important purchase for the people of Canada, the addition of a CyberKnife System at CHUM provides an opportunity for continued research and clinical investigation," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "We are thrilled to be working with such a reputable teaching facility that's had continued success in accruing patients under protocol."
In Quebec, authorization is required from a regional authority to acquire certain medical technologies, such as imaging and radiation therapy. CHUM secured approval in May 2008 and plans to install its CyberKnife System by early 2009.
About CHUM
The Centre hospitalier de l'Universite de Montreal provides specialized and ultra-specialized services to a regional and supra-regional clientele. Within its more immediate coverage area, the CHUM also provides general and specialized hospital care and services. The CHUM uses an integrated network model to carry out its five-part mandate of care, teaching, research, the assessment of technologies and health care methodologies, and the promotion of health care. Through its determined efforts to continuously improve quality of care and patient safety, the CHUM has again received accreditation from the Canadian Council on Health Services Accreditation, for the 2007-2010 period. Hotel-Dieu, Hopital Notre-Dame, and Hopital Saint-Luc make up the CHUM, with approximately 10,000 employees, 900 physicians, 270 researchers, 6,000 students and trainees and 700 volunteers providing services to over a million patients each year. www.chumontreal.qc.ca.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non- invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
About Accuray
Accuray Incorporated , based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 130 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, clinical studies, regulatory review and approval, and market acceptance and commercialization of products and services are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2007 fiscal year, as updated from time to time by our quarterly reports on Form 10- Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
CONTACT: Susan Lehman of Rockpoint Public Relations, +1-510-832-6006,
susan@rockpointpr.com, for Accuray Incorporated; or Stephanie Tomei, Public
Relations Manager of Accuray Incorporated, +1-408-789-4234,
stomei@accuray.com
Web site: http://www.accuray.com/